Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Hypomethylating drugs are the standard treatment for patients with high-risk myelodysplastic syndromes. Survival is poor after failure of these drugs; there is no approved second-line therapy. We compared the overall survival of patients receiving rigosertib and best supportive care with that of patients receiving best supportive care only in patients with myelodysplastic syndromes with excess blasts after failure of azacitidine or decitabine treatment.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

Publisher: Elsevier BV

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Apr 2016

Volume: 17

Issue: 4

Affiliations

[1 ] University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, USA. Electronic address: ggarciam@mdanderson.org.

[2 ] Hôpital St Louis/Université Paris 7, Paris, France.

[3 ] Mayo Clinic, Rochester, MN, USA.

[4 ] University of Maryland, Greenebaum Cancer Center, Baltimore, MD, USA.

[5 ] Leukemia Program, Cleveland Clinic, Cleveland, OH, USA.

[6 ] Weill Cornell Medical College, New York, NY, USA.

[7 ] Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.

[8 ] Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

[9 ] Stanford Cancer Center, Stanford, CA, USA.

[10 ] Universitätsklinikum Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany.

[11 ] Dana Farber Cancer Institute, Boston, MA, USA.

[12 ] University of Kansas Medical Center, Westwood, KS, USA.

[13 ] Universitätsklinikum zu Köln, Klinik I für Innere Medizin, Köln, Nordhein-Westfalen, Germany.

[14 ] University of Chicago Medical Center, Chicago, IL, USA.

[15 ] Froedtert Hospital and the Medical College of Wisconsin Division of Hematology and Oncology, Milwaukee, WI, USA.

[16 ] University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.

[17 ] University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, USA.

[18 ] Onconova Therapeutics, Newtown, PA, USA.

[19 ] Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Article

Publisher Item ID: S1470-2045(16)00009-7

DOI: 10.1016/S1470-2045(16)00009-7

PubMed ID: 26968357

SO-VID: 4a4d3f2e-f31d-4de5-b85a-66c0871eabe4

History

Data availability:

Comments

Comment on this article

scite_

Cited by 60

See all cited by

- Version 1